Exogene

Executive Summary

Exogene is a Cambridge, UK-based biotechnology company specializing in AI-driven discovery of T-cell receptors (TCRs) for TCR-based therapies targeting solid tumors. Traditional wet-lab methods struggle to identify safe, high-affinity TCRs against cancer antigens, limiting therapeutic options. Exogene’s machine learning platform accelerates the identification and optimization of TCRs, aiming to unlock the potential of T-cell therapies for a broad range of solid tumors. The company has progressed to Phase 3 clinical development, positioning it as a late-stage player in the immuno-oncology space. Exogene's approach leverages proprietary algorithms to screen vast libraries of TCR candidates, reducing time and cost compared to conventional methods. With a focus on challenging solid tumor targets, the company addresses a significant unmet need in oncology, where durable responses remain elusive. Exogene’s platform has the potential to expand the addressable patient population and improve outcomes in cancers with high mortality. As a private entity, the company has not disclosed financial details but continues to advance its pipeline through strategic partnerships and clinical milestones. The upcoming period is critical for validating its technology in pivotal trials and securing commercial partnerships.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 Interim Efficacy Data Readout60% success
• Q2 2026Strategic Partnership with Major Pharma for Co-Development45% success
• Q1 2027Series C Funding Round to Support Commercialization70% success